Skip to content

Nivolumab #
Find similar titles

Nivolumab, marketed as Opdivo (옵디보), is a medication used to Cancer immunotherapy. It is used as a first line treatment for inoperable or metastatic Melanoma in combination with Ipilimumab if the cancer does not have a mutation in BRAF, as a second-line treatment following treatment with ipilimumab and if the cancer has a mutation in BRAF, with a BRAF inhibitor, as a second-line treatment for squamous non-small cell lung cancer, and as a second-line treatment for renal cell carcinoma.

PD-1 target

Incoming Links #

Related Drug Classes #

Related Articles #

Suggested Pages #